King of Beiyang

"Gentlemen, if you feel this price is not suitable, we can discuss it further."

How about three million dollars? What do you guys think?

James, a representative from Parker Davis, proposed this.

Li Jingyuan shook his head: "We still think it would be better if we sold it ourselves."

Clearly, the price of three million US dollars still did not satisfy Li Jingyuan.

Jin Kaili nodded repeatedly.

Without a doubt, the new drug patents held by Oriental Pharmaceutical Company are a gold mine.

These Americans who want to buy patent licenses in North America at low prices are simply daydreaming!

"If you're unwilling to sell patent licenses, then your new drug will have no chance of being launched in the United States!" Pfizer representative Calvin's words carried a strong sense of threat.

Despite the fact that the United States prides itself on being a democratic country.

But whether it's the US government or the members of parliament, they are all backed by conglomerates.

These large companies can absolutely influence the policies of the United States.

Banning Oriental Pharmaceuticals' new drugs in the United States is not a problem at all.

"Haha! Even without the North American market, it's nothing to us. The European market alone, plus other regions, is already keeping our production capacity up."

Furthermore, if we are treated unfairly, then your medicines will not be allowed to be sold in the German Empire or any other European countries!

Li Jingyuan laughed heartily.

Although Dongfang Pharmaceutical Company was established for a short time and had a weak foundation.

But the shareholders include the royal family and the Hollen family.

The German Empire also wielded considerable influence in Europe.

If these pharmaceutical companies from the United States use unfair means to suppress Eastern pharmaceutical companies, they will inevitably face a retaliatory response.

  

Calvin and the others' expressions changed drastically.

Although they looked down on the Asian man in front of them, the presence of the other shareholders of Oriental Pharmaceutical Company made them hesitant to act rashly.

"Gentlemen, please calm down. We are discussing business, not arguing. A confrontational approach will not benefit either of us!" Smith, the representative from Wyeth, quickly tried to smooth things over.

"Okay, I'll give you one last chance. If you want patent licensing in North America, then contact your headquarters as soon as possible and submit new cooperation terms."

We will only choose one partner across the entire North American region.

Three days later, we'll choose the company that offers the best terms!

Li Jingyuan said.

The representatives from the three companies all looked very unhappy.

Their original intention was to practice driving down prices and obtain patent licenses at the lowest possible price, so that they could earn more profits.

But now it seems that this is impossible.

The representatives took their leave and then sent a telegram to the company's headquarters in the United States, inquiring about new terms of cooperation.

The executives of these pharmaceutical companies also held emergency meetings.

Without exception, everyone wanted to obtain patent licenses and dominate the North American market.

Therefore, in order to obtain patent authorization, everyone can only offer the highest possible terms.

Three days later, the conditions from all three companies were presented to Li Jingyuan.

Pfizer is willing to pay $10 million for patent licensing.

Parker-Davis is willing to pay $12 million for patent licensing.

Wyeth, on the other hand, was willing to pay $8 million for patent licensing. In addition, they would pay a $1 patent fee for every box of the drug sold.

After discussions with Lee Kyung-won, Kim Gae-ri, the Hollen family, Prince Heinrich, and others, they decided to choose Wyeth Corporation as their partner.

Although Wyeth offered the lowest price for patent licensing, Orient Pharmaceuticals valued the potential for future collaboration.

For every box of medicine sold, the Eastern Pharmaceutical Company would receive one dollar.

It's important to know that the total population of North America is over 80 million.

Of these, the United States has the largest population, exceeding 60 million. The Canadian colonies have less than 5 million. Mexico has just over 1,000. South of Mexico in Central America, there are several million more.

The largest market is, of course, the United States.

There's absolutely no problem with producing two million boxes of medicine a year in the entire North American market.

In this way, Oriental Pharmaceuticals could earn two million US dollars annually just from patent fees alone.

Perhaps the actual number of boxes of medicine sold was far more than two million.

With a steady stream of revenue, the patent fees that Oriental Pharmaceutical Company receives naturally become higher.

Li Jingyuan was also able to get a larger share of the profits.

Subsequently, the two parties signed an agreement, and Wyeth obtained a patent license for North America.

However, the matter did not end there. Li Jingyuan suggested striking while the iron was hot and selling the patent licenses in South America as well.

The buyers were also these pharmaceutical companies from the United States.

It's important to understand that as the United States has grown stronger, it has come to regard South America as its backyard.

In order to gain access to a larger market, the German Empire has been increasing its investment in South America, competing with the United States.

However, the German Empire was too far from South America, and was always at a disadvantage in the competition.

For Oriental Pharmaceuticals, South America is also beyond their reach.

If they could sell the patent licenses in South America as well, they could undoubtedly make a fortune.

At that time, the total population of South America was only around 40 million.

In terms of economy, it cannot compare with North America. Even though Brazil, Argentina, and Chile are considered the three strongest economies in South America, they are still far behind the United States.

Therefore, Pfizer ultimately secured the patent license for South America for a patent licensing fee of five million US dollars, plus a patent fee of one dollar per box of medicine sold to Eastern Pharmaceutical Company.

This patent licensing sale by Oriental Pharmaceutical Company was a complete success.

The patent licenses sold throughout the Americas totaled 13 million US dollars, which is equivalent to 52 million marks. Even converted to silver, it amounts to 10.5 million taels.

Li Jingyuan received 50 percent of it, which is 26 million marks.

Of course, 520,000 marks were to be allocated to the manager, Kim Kye-ri.

Even so, Li Jingyuan still made a fortune.

With sufficient funding, Li Jingyuan's subsequent plans could then be implemented.

"Karl, my friend, are the Hollen family acquainted with the people at the Vulcan Shipyard?" Li Jingyuan asked.

"What? My friend, are you thinking of buying a yacht?" Carl von Hollen asked.

In Europe, it's perfectly normal for people with money to buy luxury goods like yachts and enjoy life. It's also very common in high society.

Li Jingyuan shook his head: "No, I want to buy a few warships!"

"A warship?" Carl von Hollen's eyes widened immediately.

Are warships something that private individuals can own?